DBV Technologies ADR (DBVT)

Currency in USD
10.850
-0.580(-5.07%)
Real-time Data·
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.56511.590
52 wk Range
8.63026.185
Key Statistics
Prev. Close
11.43
Open
11.37
Day's Range
10.565-11.59
52 wk Range
8.63-26.185
Volume
224.85K
Average Volume (3m)
349.65K
1-Year Change
-16.9219%
Book Value / Share
0.50
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DBVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
42.080
Upside
+287.84%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

DBV Technologies ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 42.080
(+287.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy46.00+323.96%51.00MaintainOct 30, 2026
H.C. Wainwright
Buy40.00+268.66%-MaintainOct 30, 2026
Citizens
Buy47.00+333.18%55.00MaintainOct 29, 2026
Citizens
Buy55.00+406.91%-MaintainSep 30, 2026
Cantor Fitzgerald
Buy48.00+342.40%48.00MaintainSep 10, 2026

DBV Technologies ADR SWOT Analysis


Allergy Innovation
Explore DBV Technologies' groundbreaking Viaskin Peanut patch, offering a non-invasive solution for peanut allergies in children with promising clinical results
Market Potential
Delve into the projected $2 billion annual peak sales for Viaskin Peanut, driven by strong physician intent and a growing patient base
Financial Outlook
Learn about DBV's improved financial position, with $128 million in cash and potential for $180 million more, despite current cash burn concerns
Analyst Perspectives
Discover varied analyst price targets ranging from $10 to $21, reflecting optimism about DBV's future prospects in the allergy treatment market
Read full SWOT analysis

DBV Technologies ADR Earnings Call Summary for Q3/2026

  • DBV completed BLA submission for VIASKIN Peanut patch (ages 4-7) in Q3; expects priority review with 6-month timeline and toddler filing in 2027.
  • Cash position reached $165.7M including $50M from RA Capital ADS sale; runway extended into Q3 2027 amid rising commercial preparation costs.
  • Operating expenses surged 53.7% to $164.4M year-over-year; sales/marketing spending jumped 726% to $15.7M as company builds launch infrastructure.
  • Manufacturing partner Fareva Amboise addressing FDA warning letter; company targets February 2027 for pre-approval inspection readiness with comfortable timing buffer.
  • Shares rose 6.07% to $10.74 on BLA progress; management building 50-70 person sales force but declined to provide first-year revenue guidance ahead of launch.
Last Updated: 28/10/2026, 22:50
Read Full Transcript

Earnings

Latest Release
Oct 28, 2026
EPS / Forecast
-0.14 / --
Revenue / Forecast
1.6M / --
EPS Revisions
Last 90 days

DBVT Income Statement

Compare DBVT to Peers and Sector

Metrics to compare
DBVT
Peers
Sector
Relationship
P/E Ratio
−3.3x8.2x−0.2x
PEG Ratio
−0.080.240.00
Price/Book
4.6x2.7x2.6x
Price / LTM Sales
182.7x3.6x2.8x
Upside (Analyst Target)
268.0%37.0%63.4%
Fair Value Upside
Unlock16.0%9.5%Unlock

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Employees
179

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.32M3.60%134.48M
Other Institutional Investors
428.39M96.40%5.09B
Public Companies & Retail Investors
0.000.00%0.00
Total
439.71M100.00%5.22B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Management, L.P.11.64%36,576,440434,528
RA Capital Healthcare Fund, L.P.11.64%36,576,440434,528

People Also Watch

13.635
ADMA
+2.98%
593.90
LITE
-4.92%
318.59
NTRA
-1.35%
78.42
BBIO
+0.32%
8.360
BHC
+1.33%

FAQ

What Is the DBV Technologies ADR (DBVT) Stock Price Today?

The DBV Technologies ADR stock price today is 10.850 USD.

What Stock Exchange Does DBV Technologies ADR Trade On?

DBV Technologies ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for DBV Technologies ADR?

The stock symbol for DBV Technologies ADR is "DBVT."

What Is the DBV Technologies ADR Market Cap?

As of today, DBV Technologies ADR market cap is 683.050M USD.

What Is DBV Technologies ADR's Earnings Per Share (TTM)?

The DBV Technologies ADR EPS (TTM) is -0.56.

From a Technical Analysis Perspective, Is DBVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has DBV Technologies ADR Stock Split?

DBV Technologies ADR has split 2 times.

How Many Employees Does DBV Technologies ADR Have?

DBV Technologies ADR has 179 employees.

What is the current trading status of DBV Technologies ADR (DBVT)?

As of Nov 13, 2026, DBV Technologies ADR (DBVT) is trading at a price of 10.850 USD, with a previous close of 11.430 USD. The stock has fluctuated within a day range of 10.565 USD to 11.590 USD, while its 52-week range spans from 8.630 USD to 26.185 USD.

What Is DBV Technologies ADR (DBVT) Price Target According to Analysts?

The average 12-month price target for DBV Technologies ADR is 42.080 USD, with a high estimate of 47.54921478 USD and a low estimate of 29.7677505 USD. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +287.84% Upside potential.

What Is the DBVT Premarket Price?

DBVT's last pre-market stock price is 11.370 USD. The pre-market share volume is 1,000.000, and the stock has decreased by -0.060, or -0.520%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.